Key Highlights

  • Shares are trading 8.89% higher at $4.41 on Wednesday, October 28, 2026, an implied prior close of about $4.05 (calculated).
  • Second-quarter net loss narrowed to $131.0 million, or $0.25 per share, from $171.9 million, or $0.41.
  • Cash and equivalents were $545.7 million at June 30, 2026, compared with $743.3 million at December 31, 2025.
  • Phase 2 REC-4881 data are scheduled for Monday, November 2, 2026, at a Presidential Plenary session.
  • Cash runway is guided into early 2028, with 2026 cash operating expense now guided below $375 million.

Recursion Penny Stock Move: Why Are Shares Trading 8.89% Higher at $4.41?

Recursion Pharmaceuticals (NASDAQ:RXRX) shares are trading 8.89% higher at $4.41 on Wednesday, October 28, 2026, which implies a prior close of about $4.05 (calculated). The price is below $5, and heavy volume places the stock among the most active low-priced names of the session. No company release dated October 28 accompanied the move.

Recursion is a clinical-stage biotechnology company that combines automated laboratory biology, chemistry and machine learning to develop medicines for cancer and rare disease. At $4.41, the equity value is roughly $2.35 billion, using the 532.5 million weighted-average shares of the second quarter (calculated).

The nearest dated event is the Phase 2 data presentation for REC-4881 on Monday, November 2, 2026, at a Presidential Plenary I session of the CGA-IGC meeting. The candidate is a MEK1/2 inhibitor for familial adenomatous polyposis and holds Orphan Drug and Fast Track designations.

Recursion Second-Quarter Results: How Far Did Expense Cuts Narrow the Loss?

In results released on Wednesday, August 5, 2026, total revenue for the quarter ended June 30 was $7.7 million, down from $19.2 million a year earlier, as certain Roche and Genentech project phases were completed in the prior-year period.

Research and development expense fell to $89.6 million from $128.6 million, and general and administrative expense fell to $41.5 million from $46.7 million. The loss from operations was $135.0 million versus $176.2 million, and the net loss was $131.0 million, or $0.25 per share, versus $171.9 million, or $0.41.

Operating cash outflow was $105.9 million in the quarter, and the first-half outflow was $187.0 million. Cash and equivalents were $545.7 million ($556.8 million including restricted cash), down from $743.3 million at December 31, 2025.

Recursion Guidance and Partners: Does the Runway Reach Early 2028?

The company lowered its 2026 cash operating expense guidance by $15 million, to below $375 million. On current plans and without new financing, it expects cash to last into early 2028.

Genentech exercised its first Validated Target Option in neuroscience, moving a previously unexplored target into a small-molecule discovery program. Cumulative upfront and milestone payments under that collaboration total $216 million, with up to 40 potential programs, each carrying more than $300 million in potential milestones plus royalties of up to high single digits.

The Sanofi collaboration has produced $134 million in cumulative payments, with potential milestones of $343 million per program. Development candidate milestones are expected over the next six to twelve months.

What to Watch Next: REC-4881 Data on November 2 and the Second-Half Milestones

The Phase 2 REC-4881 presentation on Monday, November 2, 2026, is the first dated catalyst, followed by an FDA update on the registrational path guided for the second half of 2026. The Phase 1/2 ZINNIA trial of REC-7735 is also due to start in that period, with more REC-1245 dose-escalation data. Early safety data for REC-617 and REC-3565 are guided for the first half of 2027. Today's move is a one-session reading, and later sessions may differ.